Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Nov 20, 2019 11:22am
51 Views
Post# 30373897

RE:RE:RE:RE:May have been posted before but interesting anyway

RE:RE:RE:RE:May have been posted before but interesting anyway
Ingiboy wrote: Yes psvb we are left to speculate about this long standing acrimony between the two companies.  Thanks to new information on Shiseido Patents and the Contract between Replicel and Shiseido provided by Inv3strr we now have a clearer picture of what is really going on. 

As the share price drifts downward each day at this critical time we hear nothing from the management of Replicel.  Will we hear a detailed NR before the AGM or at the AGM?  One way or another its time for the shareholders to hear a complete description of what is going on with Shiseido and the Dermal Injector.

  It is evident that at the moment until we get the full description of what is happening with Shiseido and the Dermal Injector the company is going nowhere. It is painfully evident that some shareholders have lost faith in the future of this company and are dumping their shares.  

The result is we are now trading at $.155 which I think may be a new all time low.


All companies need cash to survive, whether through revenue or sale of stock. Replicel is no where near generating revenue. Based on the rapidly dropping share price, I believe they can't raise the required cash to keep the company alive. There only option may be to put the company up for sale. If RCH01 was worth bringing to market Shiseido would have worked out a compromise. They don't have to release their trial data let alone share. Unless there is substantial news VERY soon, Replicel is dead in the water.
Bullboard Posts